Breaking News Instant updates and real-time market news.

CAVM

Cavium

$59.57

-1.44 (-2.36%)

, XNCR

Xencor

$22.40

-0.89 (-3.82%)

04:55
08/10/17
08/10
04:55
08/10/17
04:55

Canaccord Genuity to hold a conference

37th Annual Growth Conference is being held in Boston on August 9-10.

CAVM

Cavium

$59.57

-1.44 (-2.36%)

XNCR

Xencor

$22.40

-0.89 (-3.82%)

CLH

Clean Harbors

$53.75

-0.7 (-1.29%)

DSPG

DSP Group

W

Wayfair

$72.82

-2.7 (-3.58%)

CRUS

Cirrus Logic

$56.88

0.11 (0.19%)

REGI

Renewable Energy

$11.65

-0.1 (-0.85%)

BDE

Black Diamond

$7.00

-0.05 (-0.71%)

AMD

AMD

$12.83

-0.28 (-2.14%)

MITK

Mitek Systems

$9.65

-0.1 (-1.03%)

IOTS

Adesto Technologies

$5.55

0.05 (0.91%)

BSX

Boston Scientific

$26.57

0.06 (0.23%)

KITE

Acquired by GILD 9/17

$120.98

0.85 (0.71%)

CEVA

CEVA

$42.30

-0.9 (-2.08%)

ATRA

Atara Biotherapeutics

$14.50

-0.3 (-2.03%)

SHOO

Steven Madden

$42.60

0.1 (0.24%)

  • 10

    Aug

  • 10

    Aug

  • 10

    Aug

  • 10

    Aug

  • 11

    Aug

  • 11

    Aug

  • 15

    Aug

  • 15

    Aug

  • 21

    Aug

  • 22

    Aug

  • 22

    Aug

  • 28

    Aug

  • 29

    Aug

  • 08

    Sep

  • 12

    Sep

  • 29

    Nov

CAVM Cavium
$59.57

-1.44 (-2.36%)

07/18/17
LEHM
07/18/17
DOWNGRADE
Target $9
LEHM
Underweight
AMD downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Blayne Curtis downgraded AMD (AMD) to Underweight with an unchanged price target of $9. The chipmaker closed yesterday down 12c to $13.80. The analyst is "unconvinced" that AMD products will gain enough traction to support the current valuation. He also has difficulty "getting anywhere near" the company's long-term earnings per share target of 75c. Curtis likes shares of Cavium (CAVM) and Cypress Semiconductor (CY) in the U.S. Semiconductors space heading into Q2 earnings.
08/03/17
BNCH
08/03/17
NO CHANGE
Target $80
BNCH
Buy
Cavium proving doubters wrong, says Benchmark
Benchmark analyst Gary Mobley said recent concerns over telco and data center spending sluggishness has created a buying opportunity in Cavium, which he believes proved its doubters wrong with its Q2 results and Q3 guidance. The analyst, who also notes the stock's low valuation relative to its historic levels, keeps a Buy rating and $80 price target on Cavium shares.
07/12/17
NEED
07/12/17
NO CHANGE
Target $43
NEED
Buy
Needham remains positive on Intel
After attending Intel's (INTC) official launch event for its Xeon Scalable Platform, Needham analyst N. Quinn Bolton says he came away positive on Intel's shares and expects the ramp to positively impact Cavium (CAVM), Integrated Device (IDTI), Monolithic Power (MPWR) and Microsemi (MSCC). The analyst reiterates a Buy rating and $43 price target on Intel's shares.
07/10/17
07/10/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. FLIR Systems (FLIR) upgraded to Strong Buy from Market Perform at Raymond James. 2. HP Inc. (HPQ) upgraded to Buy from Neutral at Mizuho. 3. PayPal (PYPL) upgraded to Outperform from Market Perform at Bernstein with analyst Lisa Ellis saying the company is "at the beginning, not the end, of multi-year outperformance supported by high-teens earnings appreciation." 4. Arconic (ARNC) upgraded to Overweight from Neutral at JPMorgan with analyst Seth Seifman citing valuation with the stock underperforming the S&P 500 Index by 15% over the past month. 5. Cavium (CAVM) upgraded to Buy from Hold at Jefferies with analyst Mark Lipacis saying the company will benefit as the industry undergoes a "tectonic shift towards a parallel computing model." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
XNCR Xencor
$22.40

-0.89 (-3.82%)

03/01/17
NOMU
03/01/17
INITIATION
Target $21
NOMU
Neutral
Xencor initiated with a Neutral at Nomura
Nomura initiated Xencor with a Neutral and a $21 price target.
10/04/16
PIPR
10/04/16
INITIATION
Target $35
PIPR
Overweight
Xencor initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff started Xencor with an Overweight rating and $35 price target. The analyst views the company's next-gen and bispecific antibodies as "exciting."
11/28/16
ADAM
11/28/16
NO CHANGE
Target $32
ADAM
Buy
Xencor price target raised to $32 from $27 at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Xencor to $32 from $27 citing its XmAb pipeline and attractive bispecifics capabilities and the company's mechanistic rationale for treating IgG4-RD with XmAb5871. Lee reiterated her Buy rating on Xencor shares.
12/08/16
LEER
12/08/16
NO CHANGE
Target $35
LEER
Outperform
Xencor price target raised to $35 from $30 at Leerink
Leerink analyst Michael Schmidt raised his price target for Xencor to $35 from $30 following its recent $127M equity financing, which should enable the company to accelerate and broaden development of its bispecific antibody pipeline as well as support potential pivotal trials of lead product XmAb5871 in IgG4-related disease. The analyst remains positive on Xencor's outlook as he believes the company's differentiated antibody engineering platform will continue to garner strategic interest while existing partnered and proprietary pipeline programs mature, providing upside to the current valuation. He reiterates an Outperform rating on the shares.
CLH Clean Harbors
$53.75

-0.7 (-1.29%)

08/03/17
KEYB
08/03/17
DOWNGRADE
KEYB
Sector Weight
Clean Harbors downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Joe Box downgraded Clean Harbors to Sector Weight following the disappointing Q2 saying he has reduced confidence the company can match top line growth with margin expansion.
08/03/17
BMOC
08/03/17
NO CHANGE
BMOC
Clean Harbors should be bought on weakness, says BMO Capital
BMO Capital analyst Jeffrey Silber says that the decline in Clean Harbors' stock after its results "was a bit overdone," since the company sounded "confident" and reiterated its 2017 EBITDA guidance. He recommends buying the shares on weakness.
08/07/17
LEHM
08/07/17
UPGRADE
Target $50
LEHM
Equal Weight
Clean Harbors upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Jon Windham upgraded Clean Harbors to Equal Weight saying the company's results in the second half of 2017 have less downside risk amid the steadily increasing level of industrial activity. The analyst keeps a $50 price target for the shares.
06/30/17
BMOC
06/30/17
INITIATION
BMOC
Outperform
Clean Harbors initiated on new initiatives at BMO Capital
As noted earlier, BMO Capital started coverage of Clean Harbors with a $65 price target and an Outperform rating. Analyst Jeffrey Silber says that the company should benefit from an expected increase in industrial production and its new initiatives.
DSPG DSP Group

04/25/17
WDLK
04/25/17
DOWNGRADE
Target $13
WDLK
Hold
DSP Group downgraded to Hold ahead of earnings at Wunderlich
Wunderlich analyst Matthew Robison downgraded DSP Group to Hold from Buy citing valuation with the shares up more than 20% from the close of trading on February 2. The analyst sees "insufficient opportunity for appreciation" relative to his new price target of $13, which is raised from $12. DSP reports results on April 27.
04/25/17
BNCH
04/25/17
INITIATION
BNCH
Hold
DSP Group initiated with a Hold at Benchmark
Benchmark analyst Scott Searle initiated DSP Group with a Hold saying 2017 remains a transition year.
03/17/17
ROTH
03/17/17
NO CHANGE
Target $14
ROTH
Buy
Roth Capital sees any DSP Group uncertainty as 'attractive entry point'
Roth Capital analyst Suji Desilva reiterates a Buy rating on DSP Group and regards any near-term uncertainty related to headwinds as an "attractive entry point" into a growth story driven by new product traction. The analyst also raised his price target on the shares to $14 from $12.
04/25/17
WDLK
04/25/17
DOWNGRADE
WDLK
Hold
DSP Group downgraded to Hold from Buy at Wunderlich
Wunderlich analyst Matthew Robison downgraded DSP Group to Hold.
W Wayfair
$72.82

-2.7 (-3.58%)

08/09/17
WEDB
08/09/17
NO CHANGE
WEDB
Wayfair reported 'very strong' Q2 results, says Wedbush
Wedbush analyst Seth Basham says that Wayfair reported "very strong" Q2 results. Noting that the company provided weaker than expected guidance, he says that it tends to provide conservative guidance. Basham says that the company's comparisons are set to ease, while its near-term outlook is positive. He keeps a Buy rating.
08/04/17
OPCO
08/04/17
NO CHANGE
Target $88
OPCO
Outperform
Wayfair price target raised to $88 from $80 at Oppenheimer
Oppenheimer analyst Brian Nagel raised his price target for Wayfair to $88 ahead of the company's Q2 results on August 8. Industry data has remained solid while key internal initiatives at Wayfair continue to take hold, Nagel tells investors in a pre-earnings research note. He's "optimistic" that further indications of elevated sales growth should prove another positive, near-term catalyst for shares. Nagel stays Outperform-rated on Wayfair. The online retailer closed yesterday up $3.50 to $77.33.
08/08/17
BOFA
08/08/17
NO CHANGE
Target $90
BOFA
Buy
Wayfair has potential for a large Q3 beat, says BofA/Merrill
BofA/Merrill said Wayfair beat Q2 revenue and EBITDA estimates bur reported disappointing Q3 guidance, implying a revenue deceleration. The firm's analyst notes Wayfair guided Q2 Direct Revenue growth of 37%-40% and reported 46%, and thinks there is still potential for a large Q3 bet and accelerating revenue growth. BofA/Merrill expects continue solid top-line growth and improving US EBITDA profitability to offset investor sentiment towards ongoing investment. Shares are rated Buy with a $90 price target.
08/08/17
BARD
08/08/17
NO CHANGE
Target $73
BARD
Outperform
Wayfair price target raised to $73 from $65 at Baird
Baird analyst Colin Sebastian raised his price target for Wayfair to $73 while maintaining a Neutral rating on the shares. The online retailer's Q2 results were above expectations due to "healthy" market share gains and expense timing, Sebastian tells investors in a post-earnings research note. The analyst increased his 2017 and 2018 revenue estimates for Wayfair.
CRUS Cirrus Logic
$56.88

0.11 (0.19%)

07/18/17
07/18/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMD (AMD) downgraded to Underweight from Equal Weight at Barclays with analyst Blayne Curtis saying he is "unconvinced" that AMD products will gain enough traction to support the current valuation. 2. ADP (ADP) downgraded to Equal Weight from Overweight at Barclays with analyst Darrin Peller citing valuation and the potential for lingering political driven uncertainty to impact bookings growth. The analyst lowered his price target for the shares to $105 from $110. 3. Cirrus Logic (CRUS) downgraded to Underweight from Equal Weight at Barclays with analyst Blayne Curtis saying the company's content story "stalls" in fiscal year 2019. 4. FMC Corporation (FMC) downgraded to Neutral from Buy at Seaport Global with analyst Michael Harrison saying competitor Bayer recently noted high inventories of crop protection chemicals in Brazil that creates a more cautious view of FMC's second half earnings. 5. Dominion Diamond (DDC) was downgraded to Hold from Buy at Gabelli and to Market Perform from Outperform at BMO Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/02/17
OPCO
08/02/17
NO CHANGE
OPCO
Supply chain to react positively following Apple results, says Oppenheimer
Oppenheimer analyst Rick Schafer expects the Apple (AAPL) supply chain to react positively, as Apple's guidance likely implies limited impact from any possible launch/production delays. Within the company's supply chain, the analyst continues to prefer content increase stories helping insulate from any demand softness versus expectations. His top picks in the Apple supply chain are content-driven growth stories Broadcom (AVGO) and Skyworks (SWKS). Schafer remains on the sidelines on Cirrus Logic (CRUS) and Qorvo (QRVO) heading into their respective prints tomorrow.
07/18/17
LEHM
07/18/17
UPGRADE
Target $60
LEHM
Equal Weight
Xilinx upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Blayne Curtis upgraded Xilinx (XLNX) to Equal Weight saying he sees more downside elsewhere in the U.S. Semiconductors space. The analyst raised his price target for the shares to $60 from $53. The analyst this morning downgraded both AMD (AMD) and Cirrus Logic (CRUS) to Underweight.
08/03/17
OPCO
08/03/17
NO CHANGE
OPCO
Perform
Cirrus Logic guidance suggests no major iPhone 8 content growth,says Oppenheimer
Oppenheimer analyst Rick Schafer notes that Cirrus Logic (CRUS) reported in-line Q1 and says he believes Q2 guidance confirms his view that significant gen/gen content growth in the Apple's (AAPL) iPhone 8 is unlikely. The analyst reiterates a Perform rating on Cirrus Logic's shares.
REGI Renewable Energy
$11.65

-0.1 (-0.85%)

05/05/17
ADAM
05/05/17
UPGRADE
Target $16
ADAM
Buy
Renewable Energy upgraded to Buy from Hold at Canaccord
Canaccord analyst John Quealy upgraded Renewable Energy to Buy from Hold and increased its price target to $16 from $11. After three years, the analyst now views risk/reward as compelling given the combination of a more favorable biodiesel macros, an enhanced platform, and solid management execution.
11/25/16
PIPR
11/25/16
NO CHANGE
PIPR
Piper views EPA ruling as positive for Green Plains, Renewable Energy
The Environmental Protection Agency on Wednesday released the final 2017 Renewable Volume Obligations under the Renewable Fuel Standard, Piper Jaffray analyst Brett Wong tells investors in a research note. The ruling shows support for biofuel growth across all categories, including conventional corn ethanol, Wong contends. He believes Green Plains (GPRE) and Renewable Energy (REGI) are poised to benefit on the 2017 final ruling.
11/03/16
PIPR
11/03/16
DOWNGRADE
PIPR
Neutral
Renewable Energy downgraded to Neutral from Overweight at Piper Jaffray
BDE Black Diamond
$7.00

-0.05 (-0.71%)

08/02/17
STFL
08/02/17
UPGRADE
Target $8
STFL
Buy
Black Diamond upgraded to Buy from Hold at Stifel
03/07/17
STFL
03/07/17
DOWNGRADE
STFL
Hold
Black Diamond downgraded to Hold from Buy at Stifel
03/07/17
STFL
03/07/17
DOWNGRADE
STFL
Hold
Black Diamond downgraded on slow profit rebound, lack of catalysts at Stifel
As noted earlier, Stifel downgraded Black Diamond to Hold from Buy. As reasons for the downgrade, Stifel analyst Jim Duffy cited slow profitability increases and lack of fundamental catalysts. Target to $6 from $5.50.
08/02/17
STFL
08/02/17
UPGRADE
STFL
Buy
Black Diamond upgraded on potential acquisition at Stifel
As noted earlier, Stifel upgraded Black Diamond to Buy from Hold. Analyst Jim Duffy says he believes that, based on comments made at an investor event, BlackDiamond "is close to an acquisition of a profitable, cash generating company" that will allow Black Diamond to use its NOLs. The analyst thinks that such an acquisition would raise the stock's value to exceed $8, and he remains upbeat on its fundamentals.
AMD AMD
$12.83

-0.28 (-2.14%)

07/28/17
MACQ
07/28/17
NO CHANGE
Target $40
MACQ
Outperform
Intel long-term growth sustainable, says Macquarie
Macquarie analyst Srini Pajjuri said Intel (INTC) reported a solid quarter and raised its FY17 outlook. The analyst believes PC inventory risk is largely in guidance and DCG growth was better, and thinks the best is yet to come for Purley. The analyst believes 8-10% growth is sustainable longer term as any gains by AMD (AMD) should be limited to the low end and Purley's AI/ML workload performance should sustain Intel's lead in inferencing against Nvidia (NVDA). Pajjuri rates Intel an Outperform with a $40 price target.
07/31/17
WELS
07/31/17
NO CHANGE
WELS
Wells Fargo downgrades Semiconductor sector to Market Weight
Wells Fargo analyst David Wong downgraded the Semiconductor sector to Market Weight from Overweight. Recent earnings reports from chip companies suggest that year-over-year growth will likely plateau or perhaps even decelerate over the next few months, Wong tells investors in a research note. He believes many chip stocks now have "elevated multiples" off calendar 2018 earnings estimates. Wong still sees good investment opportunities in some specific stocks, however, and reiterates Outperform ratings on Intel (INTC), Qualcomm (QCOM), Micron (MU), AMD (AMD), Skyworks (SWKS) and Microsemi (MSCC).
08/08/17
WELS
08/08/17
NO CHANGE
WELS
AMD competitive position has improved, says Wells Fargo
Wells Fargo says that AMD's "smooth execution on important new product introductions has significantly improved" its "competitive position in microprocessors and graphics chips." The firm quotes a third party researcher as saying that the company has started to gain share in server processors.
07/26/17
07/26/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AMD (AMD) initiated with an Outperform at Baird. 2. Altice USA (ATUS) initiated with a Market Perform at Wells Fargo. 3. Callidus Software (CALD) initiated with a Buy at Jefferies. 4. Jones Lang LaSalle (JLL) initiated with a Neutral at UBS. 5. Ocular Therapeutix (OCUL) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MITK Mitek Systems
$9.65

-0.1 (-1.03%)

03/21/17
BNCH
03/21/17
NO CHANGE
Target $10
BNCH
Buy
Ariba deal potentially expands Mitek addressable market, says Benchmark
Benchmark analyst Mark Schappel views Mitek's (MITK) announcement that it is enabling business-to-business mobile payments across SAP (SAP) Ariba's payments network favorably, stating that it has the potential to expand the company's addressable market and accelerate growth. However, he notes that he does not expect the Ariba Network partnership to generate material revenue until mid-FY18, at the earliest. Schappel, who continues to rate Mitek his top small-cap, keeps a Buy rating and $10 price target on the stock.
12/19/16
ROTH
12/19/16
NO CHANGE
Target $9
ROTH
Buy
Roth Capital remains bullish on Mitek Systems
Roth Capital analyst Darren Aftahi remains "quite bullish" on Mitek Systems (MITK), and believes its Mobile ID business should continue to flourish. The analyst sees Gemalto's (GTOMY) recent acquisition of 3M's (MMM) identity management business as not being a competitive threat to Mitek Systems' consumer-facing mobile business, as most of 3M's business was focused around hardware, chip-sets and centered on government-facing entities. He reiterates a Buy rating and $9 price target on Mitek Systems' shares.
12/08/16
BTIG
12/08/16
INITIATION
Target $10
BTIG
Buy
Mitek Systems initiated with a Buy at BTIG
BTIG analyst Joel Fishbein initiated Mitek Systems with a Buy and a $10 price target.
IOTS Adesto Technologies
$5.55

0.05 (0.91%)

08/31/16
ROTH
08/31/16
INITIATION
Target $4
ROTH
Buy
Adesto Technologies assumed with a Buy at Roth Capital
Roth Capital analyst Suji Desilva assumed coverage of Adesto Technologies with a Buy rating and $4 price target.
BSX Boston Scientific
$26.57

0.06 (0.23%)

07/17/17
COWN
07/17/17
NO CHANGE
Target $31
COWN
Outperform
Boston Scientific set up favorably for Q2, says Cowen
Cowen analyst Joshua Jennings believes Boston Scientific can retain its position as one of the premier large cap Med-Tech growth stories and does not expect Q2 results to slow its momentum. He believes its top line growth performance will remain and said it is possible to see another positive guidance revision. Jennings reiterated his Outperform rating and $31 price target on Boston Scientific shares.
06/28/17
STFL
06/28/17
NO CHANGE
STFL
Boston Scientific Analyst Day 'impressive,' says Stifel
Stifel analyst Rick Wise says that Boston Scientific's Analyst Day was "impressive. " He says that the company's 2018-2020 goals are "at least in-line" with the consensus outlook, and he continues to be upbeat about the company's longer term outlook. Wise raised his price target on the shares to $32 from $30 and keeps a Buy rating.
06/28/17
MSCO
06/28/17
NO CHANGE
Target $30
MSCO
Overweight
Boston Scientific long-term outlook faster than expected, says Morgan Stanley
Morgan Stanley analyst David Lewis said Boston Scientific's analyst day increased his conviction the company is now a structurally faster grower than previously expected and offers a unique top to bottom profile. The analyst sees continued innovation, market share gains, and emerging market penetration and said the $2B Structural Heart and balance sheet optionality are not fully reflected in valuation. Lewis rates Boston Scientific an Overweight with a $30 price target.
06/28/17
RBCM
06/28/17
NO CHANGE
RBCM
RBC sees competing bid for Spectranetics as unlikely
RBC Capital analyst Glenn Novarro believes a competing bid for Spectranetics (SPNC) is unlikely and that Philips' (PHG) offer "signals a high probability of an on-time approval." The analyst notes Boston Scientific (BSX) is already developing a drug-eluting stent and a drug-coated balloon for peripheral artery disease and that Abbott (ABT) is integrating St. Jude while also soon closing its buyout of Alere (ALR).
KITE Acquired by GILD 9/17
$120.98

0.85 (0.71%)

07/13/17
MAXM
07/13/17
DOWNGRADE
MAXM
Hold
Kite Pharma downgraded to Hold from Buy at Maxim
07/10/17
JEFF
07/10/17
NO CHANGE
Target $121
JEFF
Buy
Jefferies ups Kite target to $121 on 'relatively benign' FDA docs
Jefferies analyst Biren Amin raised his price target for Kite Pharma (KITE) shares to $121 from $101 after the FDA posted briefing documents ahead of the July 12 committee meeting disusing Novartis' (NVS) CAR-T therapy CTL019. The documents for the first CAR-T therapy seem "relatively benign," Amin tells investors in a research note. The FDA's view of CAR-T therapies looks in-line with expectations, but the agency may require long-term follow-up of patients to assess for risk of secondary malignancies, Amin writes. He keeps a Buy rating on Kite Pharma. The stock in late morning trading is down 3% to $102.55.
07/13/17
07/13/17
DOWNGRADE

Hold
Kite Pharma downgraded to Hold at Maxim
As previously reported, Maxim analyst Jason McCarthy downgraded Kite Pharma to Hold from Buy as he believes approval and success in relapsed/refractory blood cancers is already being factored in at the stock's current valuation. While "there is much more to come" from T-cell based oncology therapies, the focus for Kite is set to shift to "not if, but when and how much," McCarthy tells investors.
07/13/17
SBSH
07/13/17
NO CHANGE
SBSH
Novartis vote bodes well for Kite and Juno, says at Citi
Citi analyst Robyn Karnauskas believes the FDA's unanimous vote in favor of Novartis' (NVS) CAR-T bodes well for Kite Pharma (KITE) and Juno Therapeutics (JUNO). Yesterday's panel meeting provides a preview of what Kite can expect ahead of its November 29 FDA action date, Karnauskas tells investors in a research note. She believes the expert commentary from the panel has "overarching implications" for Kite and Juno, both of which are developing CAR-T therapies for multiple indications.
CEVA CEVA
$42.30

-0.9 (-2.08%)

07/31/17
ROTH
07/31/17
NO CHANGE
Target $53
ROTH
Buy
CEVA price target raised to $53 from $47 at Roth Capital
Roth Capital analyst Suji Desilva raised his price target for CEVA to $53 from $47 ahead of results as he believes it represents a differentiated investment opportunity in high-margin licensing and royalty revenue, levered to growth across communications and Internet of Things applications. The analyst reiterates a Buy rating on the shares.
08/09/17
BNCH
08/09/17
NO CHANGE
BNCH
Buy
CEVA could be pressured by latest in Qualcomm-Apple fight, says Benchmark
Benchmark analyst Gary Mobley noted that Qualcomm (QCOM) announced that the ITC has commenced an investigation into Apple's (AAPL) use of certain mobile devices, radio frequency and processing components" as the companies continue their legal fight over disputed royalties. Intel (INTC) and Qualcomm currently split the iPhone 7 thin modem business and it is expected they'll also evenly split the iPhone 8 business, said Mobley, who noted that CEVA (CEVA) could lose $2M-$2.5M in annual royalties if the Intel-based phones are banned for U.S. import. He keeps a Buy rating on CEVA shares, which are down fractionally in early trading.
05/05/17
ROTH
05/05/17
NO CHANGE
Target $47
ROTH
Buy
CEVA price target raised to $47 from $40 at Roth Capital
Roth Capital analyst Suji Desilva raised his price target for CEVA to $47 from $40 as he is encouraged by the continued licensing strength and unchanged 2017 expectation for royalty growth. The analyst reiterates a Buy rating on the shares.
06/05/17
BNCH
06/05/17
NO CHANGE
Target $50
BNCH
Buy
CEVA price target raised to $50 from $42 at Benchmark
After meeting with CEVA management, Benchmark analyst Gary Mobley raised his price target on the stock to $50 from $42, stating that his talks confirmed "robust" growth trends for both royalties and license revenue. He keeps a Buy rating on CEVA shares.
ATRA Atara Biotherapeutics
$14.50

-0.3 (-2.03%)

03/15/17
SBSH
03/15/17
NO CHANGE
Target $10
SBSH
Sell
Citi sees 50% downside risk in shares of Atara
Citi analyst Yigal Nochomovitz reiterates a Sell rating and $10 price target on shares of Atara Biotherapeutics following the stock's 40% rally this morning. The price target reflects 50% downside from current levels, the analyst points out. The stock rally came in the absence of new clinical data and with minimal updates on the pipeline, Nochomovitz tells investors in a research note. He continues to believe Atara's markets are relatively niche.
12/14/16
SBSH
12/14/16
NO CHANGE
Target $8
SBSH
Sell
Citi says Atara Biotherapeutics sell thesis is working
Citi analyst Yigal Nochomovitz believes his thesis on Atara Biotherapeutics is working after the company this week said it will not be able to start Phase 3 trials by the end of 2016. The analyst keeps a Sell rating on the shares with an $8 price target.
11/21/16
WBLR
11/21/16
NO CHANGE
WBLR
Outperform
William Blair views Atara as 'overlooked and misunderstood'
William Blair analyst John Sonnier feels Atara Biotherapeutics, following last year's failure of a molecularly targeted pipeline candidate in a Phase II protein-energy wasting trial, has been "overlooked and misunderstood" by investors. Since the failure, the company has made "important advances with a differentiated T-cell platform," with plans to initiate two Phase III clinical trials by the end of this year, Sonnier tells investors in a research note. He believes Atara shares are fundamentally undervalued and reiterates an Outperform rating on the shares.
10/24/16
JEFF
10/24/16
INITIATION
Target $23
JEFF
Buy
Atara Biotherapeutics assumed with a Buy at Jefferies
Jefferies analyst Gena Wang assumed coverage of Atara Biotherapeutics with a Buy rating and $23 price target. The company's off-the-shelf cytotoxic T-lymphocytes technology could offer differentiated advantages, Wang contends.
SHOO Steven Madden
$42.60

0.1 (0.24%)

02/27/17
02/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Steven Madden (SHOO) upgraded to Buy from Neutral at B. Riley by analyst Jeff Van Sinderen, who said last week's footwear show and latest channel checks underscore the company's potential for growth. 2. Illumina (ILMN) upgraded to Buy from Hold at Evercore ISI by analyst Ross Muken following customer checks that lead him to above consensus revenue forecasts. Muken believes Illumina will sell 750-1,300 NovaSeq boxes over the next several years as sequencing enters a new era of utility. 3. Carnival (CCL) upgraded Buy from Hold by Argus analyst John Staszak, who now believes that "continued " improvement in demand for cruises will improve the company's earnings and margins. 4. Cempra (CEMP) upgraded to Buy at Roth Capital by analyst Michael Higgins after the company announced positive Phase 3 results in the first of two skin infection studies with Taksta, and ahead of bone data in 2017. The analyst also raised his price target on the shares to $8 from $2.50. 5. Unilever (UN) upgraded to Neutral from Underperform at BofA Merrill Lynch by analyst David Hayes, citing valuation and his belief that the strategic review could accelerate margin development targets over the next 4 years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/07/17
SBSH
03/07/17
NO CHANGE
SBSH
Steven Madden added to "Value Creators" SMID Focus List at Citi
Citi analyst Scott Chronert added Steven Madden (SHOO) to his firm's "Value Creators" SMID Focus List while removing Berry Plastics (BERY). Steven Madden is well positioning for current footwear fashion trends, Chronert tells investors in a research note.
02/27/17
RILY
02/27/17
UPGRADE
Target $45
RILY
Buy
Steven Madden upgraded to Buy from Neutral at B. Riley
B. Riley analyst Jeff Van Sinderen upgraded Steven Madden to Buy and raised his price target for the shares to $45 from $40. Last week's footwear show and latest channel checks underscore the company's potential for growth, Van Sinderen tells investors in a research note.
02/24/17
ADAM
02/24/17
NO CHANGE
Target $45
ADAM
Buy
Steven Madden price target raised to $45 from $40 at Canaccord
Canaccord analyst Camilo Lyon raised his price target on Steven Madden to $45 from $40 following meetings with management. The analyst sees multiple trends spurring a strong spring season and sees the company as the only one in the firm's coverage that can continue to thrive in the challenged retail landscape because its supply model is geared to respond in near-real time to changing consumer tastes. Lyon reiterated his Buy rating on Steven Madden shares.

TODAY'S FREE FLY STORIES

16:37
11/24/17
11/24
16:37
11/24/17
16:37
General news
Money Supply M2 Weekly Change data reported »

Week of 11/13 Money…

16:37
11/24/17
11/24
16:37
11/24/17
16:37
General news
Fed Balance Sheet Level data reported »

Week of 11/22 Fed Balance…

$NSD

NASDAQ Market Internals

16:17
11/24/17
11/24
16:17
11/24/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
11/24/17
11/24
16:16
11/24/17
16:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
11/24/17
11/24
16:15
11/24/17
16:15
General news
Breaking General news story  »

Week of 11/13 Money…

16:15
11/24/17
11/24
16:15
11/24/17
16:15
General news
Breaking General news story  »

Week of 11/22 Fed Balance…

RIC

Richmont Mines

16:01
11/24/17
11/24
16:01
11/24/17
16:01
Hot Stocks
Breaking Hot Stocks news story on Richmont Mines »

Richmont Mines trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGLN

Magellan Health

$83.65

0.35 (0.42%)

15:18
11/24/17
11/24
15:18
11/24/17
15:18
Conference/Events
Magellan Health to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

SGMS

Scientific Games

$52.00

-0.2 (-0.38%)

15:17
11/24/17
11/24
15:17
11/24/17
15:17
Conference/Events
Scientific Games to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
11/24/17
11/24
15:17
11/24/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
11/24/17
11/24
15:16
11/24/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
11/24/17
11/24
14:17
11/24/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
11/24/17
11/24
14:16
11/24/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$21.07

0.44 (2.13%)

, WMT

Wal-Mart

$96.62

0.21 (0.22%)

13:29
11/24/17
11/24
13:29
11/24/17
13:29
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

M

Macy's

$21.07

0.44 (2.13%)

WMT

Wal-Mart

$96.62

0.21 (0.22%)

TGT

Target

$55.88

-1.61 (-2.80%)

BASFY

BASF

$27.39

-0.13 (-0.47%)

TEVA

Teva

$13.70

0.22 (1.63%)

CBS

CBS

$56.54

0.3 (0.53%)

DISH

Dish

$50.43

0.39 (0.78%)

ASX

Advanced Semiconductor

$7.07

0.76 (12.04%)

SPIL

Siliconware Precision

$7.94

-0.05 (-0.63%)

QD

Qudian

$12.22

-3.93 (-24.33%)

BABA

Alibaba

$191.19

1.35 (0.71%)

VIPS

Vipshop

$8.14

-0.3 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Nov

  • 20

    Feb

  • 18

    Mar

AFL

Aflac

$85.00

-0.05 (-0.06%)

13:26
11/24/17
11/24
13:26
11/24/17
13:26
Conference/Events
Aflac to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

GBL

GAMCO Investors

, WTS

Watts Water

$72.65

0.15 (0.21%)

13:26
11/24/17
11/24
13:26
11/24/17
13:26
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, Watts Water »

Gabelli reports 6.69%…

GBL

GAMCO Investors

WTS

Watts Water

$72.65

0.15 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

CC

Chemours

$53.31

0.45 (0.85%)

13:23
11/24/17
11/24
13:23
11/24/17
13:23
Conference/Events
Chemours to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

$NSD

NASDAQ Market Internals

13:17
11/24/17
11/24
13:17
11/24/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
11/24/17
11/24
13:16
11/24/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$35.74

0.16 (0.45%)

13:09
11/24/17
11/24
13:09
11/24/17
13:09
Conference/Events
Aimmune to hold an investor symposium »

Investor Symposium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

PN

Patriot National

12:57
11/24/17
11/24
12:57
11/24/17
12:57
Hot Stocks
Breaking Hot Stocks news story on Patriot National »

Patriot National trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCM

Cheetah Mobile

$12.02

-0.4 (-3.22%)

12:55
11/24/17
11/24
12:55
11/24/17
12:55
Options
Cheetah Mobile put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$44.47

0.1828 (0.41%)

12:53
11/24/17
11/24
12:53
11/24/17
12:53
Conference/Events
General Motors holds an investor an analyst webcast »

Management hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 09

    Jan

  • 16

    Jan

12:45
11/24/17
11/24
12:45
11/24/17
12:45
General news
Breaking General news story  »

Week of 11/24…

EBAY

eBay

$35.94

-0.02 (-0.06%)

, OSTK

Overstock.com

$61.05

0.6 (0.99%)

12:43
11/24/17
11/24
12:43
11/24/17
12:43
Periodicals
Adobe: Black Friday online sales up 18.4% y/y as of 10:00 am ET, CNBC says »

According to Adobe…

EBAY

eBay

$35.94

-0.02 (-0.06%)

OSTK

Overstock.com

$61.05

0.6 (0.99%)

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.